58084-48-3

Usage

Uses

Used in Pharmaceutical Industry:
Ergolin-8-amine,9,10-didehydro-6-methyl-, (8a)(9CI) is used as a pharmaceutical compound for its potential therapeutic effects on the central nervous system. Its structural similarity to neurotransmitters allows it to interact with the brain's chemical messengers, making it a candidate for the treatment of neurological disorders.
Used in Parkinson's Disease Treatment:
In the field of neurology, Ergolin-8-amine,9,10-didehydro-6-methyl-, (8a)(9CI) is used as a potential treatment for Parkinson's disease. Its psychoactive properties and impact on neurotransmitters may help alleviate symptoms associated with this movement disorder.
Used in Migraine Treatment:
Ergolin-8-amine,9,10-didehydro-6-methyl-, (8a)(9CI) is also used as a potential treatment for migraines. Its influence on neurotransmitters may help reduce the frequency and severity of migraine attacks by modulating the brain's pain response mechanisms.

Upstream product

• 55584-33-3 N-(6-methyl-9,10-didehydro-ergolin-8α-yl)-acetamide 
• 18016-80-3 lisuride 
• 5256-60-0 6-methyl-9,10-didehydro-ergoline-8-carboxylic acid hydrazide 

Relevant academic research and scientific papers

NOVEL NEUROMODULATORY COMPOUNDS

Provided herein are novel neuromodulatory compounds and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease, using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein. In other embodiments, provided herein are methods of agonizing dopaminergic D2 receptors and/or antagonizing or inhibiting activity of receptors such as the 5-HT2 receptors using the compounds and compositions disclosed herein.

Process for the preparation of ergoline derivatives

A process for preparing an ergoline of the formula STR1 wherein C9 ----C10 is a CC single or double bond, R1 is hydrogen or CONR2, R being hydrogen, methyl, or ethyl, and wherein NR' is in the α- or β- position, R2 is lower alkyl of up to 3 carbon atoms, and the salts thereof, comprises treating the corresponding ergolinyl carboxylic acid amide with lead(IV) acetate in an aprotic polar solvent; reacting the intermediarily formed corresponding isocyanate with water or with a reactive amine of up to 4 carbon atoms, (e.g. a mono- or dialkylamine of up to 4-C atoms); and, optionally, treating the resultant product with an acid to form the corresponding salt.